MIND MEDICINE MINDMED INC. [MMEDF: OTCQB]

3.641 0.391 (12.03%) 01/21/2021 Delayed 15 minutes

Open	$3.39	Daily Range	$3.27-$3.68
Prev. Close	$3.25	52 Week Range	$0.0833-$5.07
Volume	6,204,382

Quote Data Realtime

Inside Quote
Bid	Ask	Last Inside Change
$3.64 x 2000 shares	$3.65 x 8600 shares	01/21 5:00 PM EST

Level II Quote Montage

BID

ASK

MMID	Bid Price	Bid Size	Date/Time
NITE	3.64	1000	15:59
CSTI	3.64	1000	15:59
ETRF	3.63	1377	15:59
GTSM	3.63	1000	15:59
OTCX	3.62	2200	15:59
JANE	3.61	5000	15:59
CDEL	3.61	20709	15:59
MAXM	3.50	5000	13:33
PAUL	3.20	100	01/20
CANT	2.73	100	01/19
VNDM	2.73	100	01/20
LAFC	2.52	100	12/22
VERT	2.00	100	12/23
PUMA	1.23	100	08:10
BGCE	1.00	100	12/15
MCAP	0.78	1000	15:59
VALX	U		15:59

MMID	Ask Price	Ask Size	Date/Time
JANE	3.65	5000	15:59
OTCX	3.65	3600	15:59
CDEL	3.66	200	15:59
ETRF	3.66	100	15:59
NITE	3.67	400	15:59
GTSM	3.80	500	15:57
VERT	4.00	100	01/05
PAUL	4.05	100	09:15
VNDM	4.25	100	01/20
CSTI	4.65	100	15:59
PUMA	5.25	100	08:10
LAFC	5.45	100	12/14
MAXM	5.45	100	15:31
MCAP	5.78	100	15:59
BGCE	5.98	100	12/15
CANT	6.00	100	12:45
VALX	U		15:59

The quotes displayed here are published by market makers on the OTC Markets Group Inc. electronic inter-dealer quotation and trading system for OTC securities. Please see Terms of Service and Risk Warning for more information.

MMID - Market maker quotation published in OTC Link that meets the Inside market | MMID - Market maker quotation published in OTC Link | cMMID - Closed quote | Unpriced - Unpriced quote in OTC Link | MMIDu - Unsolicited market maker quotation published in OTC Link

Press Release

Press Release

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

BASEL, Switzerland, Jan. 20, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered […]